Life Sciences Licensing, Collaborations & Joint Ventures

top life sciences law firms

Leaders in the life sciences industry turn to Ropes & Gray’s global licensing practice for creative solutions to their most pressing legal and business needs.

Contact

“Clients note the team's thorough approach and comprehensive coverage of strategic advisory services and transactional counseling.” Chambers USA
“They have tremendous experience in complex licensing and partnering work.” Client and Market Sources, Chambers USA
“This firm fields strong teams of practitioners in both corporate and IP areas relating to life sciences. It is particularly recommended for its work in M&A and complex licensing matters.” Chambers USA

Overview

With one of the largest licensing practices in the world, Ropes & Gray has the knowledge and experience to help our global clients succeed in today’s life sciences industry.

Our team of licensing attorneys represents public and private pharmaceutical, biotechnology and medical device companies, and research institutions in structuring and negotiating all forms of complex commercial agreements. 

We also have extensive experience in transactions involving early and late development stage products, approved products, platform technologies and services specific to the life sciences industry.

We regularly advise our clients on:

  • Licensing & collaboration agreements
  • Outsourcing agreements
  • Co-promotion, marketing & distribution agreements
  • Manufacturing & supply agreements
  • Technology transfer arrangements
  • Joint ventures

Experience

Ropes & Gray’s life sciences licensing team has extensive experience representing public and private life sciences companies in structuring all types of collaboration agreements. Recent representations include:

  • Vertex Pharmaceuticals in its $2.6 billion strategic research and collaboration agreement with CRISPR Therapeutics.
  • Boehringer Ingelheim in a $595 million global license and collaboration agreement with AbbVie to jointly develop and commercialize a biologic IL-23 antibody for the treatment of psoriasis and other immunological indications.
  • Sarepta Therapeutics in its $585M-plus exclusive license and collaboration agreement with Summit Therapeutics for the European rights to Summit’s utrophin modulator pipeline for the treatment of Duchenne Muscular Dystrophy.
  • The Broad Institute of MIT and Harvard in a global licensing agreement with Monsanto Company for the use of the CRISPR-Cas genome-editing technology in agriculture. The agreement is the Broad Institute’s first commercial license for use of the CRISPR technology in agriculture.
  • A large global pharmaceutical company in its worldwide license from a multinational research-based biopharmaceutical company of an IL-23 antibody being developed for Crohn’s disease that may also be developed for other GI indications. The deal includes a $250 million upfront payment, development and sales based milestones of $1.27 billion and tiered royalties on net sales.
  • Heptares Therapeutics, a clinical-stage company targeting G protein-coupled receptors, in a $10 million licensing and product development agreement with Teva Pharmaceuticals to exploit small molecule calcitonin gene-relate peptide antagonists discovered by Heptares for treatment of migraine headaches.
  • Proteostasis Therapeutics, in a $1.2 billion worldwide collaboration deal to develop and commercialize Infinity’s duvelisib for the treatment of patients with cancer.
  • Alexion Pharmaceuticals in a $265 million strategic collaboration with Blueprint Medicines to discover, develop and commercialize novel drug candidates for an undisclosed activated kinase target which is the cause of a rare genetic disease.
  • Pfizer, in a joint collaboration with Merck KGaA to develop and commercialize an anti-PD-L1 antibody to treat tumors. Under the terms of the agreement, Merck will receive $850 million upfront and $2 billion in regulatory and commercial milestone payments.